ChemoCentryx (CCXI) Crashes 55% on Mixed AdComm Results, Gets Downgraded at Five Firms

Pre-Open Stock Movers 05/07: (IBIO) (BILL) (AXON) Higher; (CCIX) (APPN) (FROG) Lower (more...)

May 7, 2021 9:20 AM EDT

Pre-Open Stock Movers

ChemoCentryx, Inc., (Nasdaq: CCXI) 55.8% LOWER; mixed vote from FDA Arthritis Advisory Committee on avacopan for the treatment of Antineutrophil Cytoplasmic Autoantibody (ANCA)-associated vasculitis (or AAV). Multiple analyst downgrades.

iBio, Inc. (NYSE: IBIO) 43% HIGHER; provided an update on its IBIO-201 program and reported on its progress in developing a second-generation subunit vaccine candidate, IBIO-202, being designed for the prevention of SARS-CoV-2 infection.

Bill.com (NYSE:... More

Raymond James Downgrades ChemoCentryx (CCXI) to Outperform

May 7, 2021 7:38 AM EDT

Raymond James analyst Steven Seedhouse downgraded ChemoCentryx (NASDAQ: CCXI) from Strong Buy to Outperform with a price target of $51.00 (from $120.00).

The analyst commented, "To be clear, our downgrade to Outperform from Strong Buy is based on reduced conviction in avacopan being approved by July 7 PDUFA given Thursdays AdCom discussion and vote. However, if approved we still think avacopan is a... More

ChemoCentryx (CCXI) sinks 45% as trading resumes following mixed FDA AdCom

May 7, 2021 7:15 AM EDT

ChemoCentryx (NASDAQ: CCXI) sinks 45% as trading resumes following mixed FDA AdCom.

... More

SVB Leerink Downgrades ChemoCentryx (CCXI) to Market Perform

May 7, 2021 7:01 AM EDT

SVB Leerink analyst Joseph Schwartz downgraded ChemoCentryx (NASDAQ: CCXI) from Outperform to Market Perform with a price target of $17.00.

For an analyst ratings summary and ratings history on ChemoCentryx click here. For more ratings news on ChemoCentryx click here.

Shares of ChemoCentryx closed at $27.49 yesterday.

... More

ChemoCentryx (CCXI) Reports Mixed FDA AdCom Vote For Avacopan

May 7, 2021 6:48 AM EDT

ChemoCentryx, Inc., (Nasdaq: CCXI), today announced the outcome of the FDA Arthritis Advisory Committee on avacopan for the treatment of Antineutrophil Cytoplasmic Autoantibody (ANCA)-associated vasculitis (or AAV). In the final part of the public meeting, the Committee voted on three questions presented by the FDA:

The Committee vote split 9-9 on the first question, whether the efficacy data support approval of avacopan for the treatment of adult patients with AAV (granulomatosis with... More

UPDATE: Stifel Downgrades ChemoCentryx (CCXI) to Hold

May 7, 2021 4:01 AM EDT

(Updated - May 7, 2021 5:14 AM EDT)

Stifel analyst Dae Gon Ha downgraded ChemoCentryx (NASDAQ: CCXI) from Buy to Hold with a price target of $26.00 (from $93.00).

THe analyst comments "We are downgrading CCXI to Hold (from Buy) with a reduced TP $26 (from $93 previously) following a... More

UPDATE: JPMorgan Downgrades ChemoCentryx (CCXI) to Underweight

May 7, 2021 4:01 AM EDT

(Updated - May 7, 2021 5:12 AM EDT)

JPMorgan analyst Anupam Rama downgraded ChemoCentryx (NASDAQ: CCXI) from Neutral to Underweight with a price target of $17.00 (from $57.00).

The analyst comments "We hold an Underweight rating on CCXI shares. ChemoCentryx is a biotechnology company with a focus on developing oral drugs that target the chemokine system, which is... More

Piper Sandler Downgrades ChemoCentryx (CCXI) to Neutral

May 6, 2021 7:04 PM EDT

Piper Sandler analyst Edward Tenthoff downgraded ChemoCentryx (NASDAQ: CCXI) from Overweight to Neutral with a price target of $25.00.

For an analyst ratings summary and ratings history on ChemoCentryx click here. For more ratings news on ChemoCentryx click here.

Shares of ChemoCentryx closed at $27.49 yesterday.

... More

ChemoCentryx (CCXI) Halted, News Pending

May 6, 2021 6:55 AM EDT

ChemoCentryx (NASDAQ: CCXI) Halted, News Pending

... More